Health Economics›Gestational trophoblastic neoplasia›Low-risk disease, all lines of therapy

Low-risk disease, all lines of therapy

Gestational trophoblastic neoplasia · 4 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Dactinomycin monotherapy Variant #01	—	R 18 019	28d	—	—	—	—	—
EMA/CO Variant #01	—	R 6 289	7d	—	—	—	—	—
Mercaptopurine and Methotrexate Variant #05	—	R 2 336	14d	—	—	—	—	—
Methotrexate monotherapy Partial	—	—	—	~2.6 mo	~6.7 mo	—	—	10

4 of 4 regimens shown